NasdaqCM - Nasdaq Real Time Price ? USD Liquidia Corporation (LQDA) Follow Compare 10.65 +0.50 (+4.93%) At close: 4:00 PM EST 10.60 -0.05 (-0.47%) After hours: 5:09 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 3 US Growth Stocks With At Least 10% Insider Ownership As geopolitical tensions rise, the U.S. stock market has experienced early declines, with major indices such as the Dow Jones Industrial Average and S&P 500 slipping amid investor concerns. In this environment of uncertainty, stocks with substantial insider ownership can offer a unique perspective on potential growth opportunities, as insiders may have confidence in their company's long-term prospects despite short-term market fluctuations. Simply Wall St. ? 3 days ago LQDA +4.93% AEYE GHLD Liquidia Third Quarter 2024 Earnings: Beats Expectations Liquidia ( NASDAQ:LQDA ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.45m (up 21% from 3Q 2023). Net... Simply Wall St. ? 7 days ago LQDA +4.93% Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ... Liquidia Corp (LQDA) outlines promising clinical progress and strategic partnerships while navigating regulatory and financial hurdles. GuruFocus.com ? 8 days ago LQDA +4.93% Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates Liquidia Technologies (LQDA) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? Zacks ? 9 days ago LQDA +4.93% Liquidia Corporation Reports Third Quarter 2024 Financial Results?and Provides Corporate Update Received tentative approval from the FDA for YUTREPIA? (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appealStrengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov. 13, GlobeNewswire ? 9 days ago LQDA +4.93% Liquidia to Present at the Stifel 2024 Healthcare Conference MORRISVILLE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET. Access to the live webcasts will be available to investors and other interested parties via Liquidia’s website at https://liquidia.com/invest GlobeNewswire ? 10 days ago LQDA +4.93% Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Zacks ? 15 days ago ACLX LQDA +4.93% Investors in Liquidia (NASDAQ:LQDA) have seen stellar returns of 186% over the past five years When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can... Simply Wall St. ? 15 days ago LQDA +4.93% Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024 MORRISVILLE, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today it will now report its third quarter 2024 financial results on Wednesday, November 13, 2024. The date has been moved to accommodate for SEC filing rules impacted by the federal holiday observed on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time GlobeNewswire ? 16 days ago LQDA +4.93% Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024 MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https:/ GlobeNewswire ? 18 days ago LQDA +4.93% Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 21 days ago YMAB +3.07% LQDA +4.93% Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Liquidia Technologies (LQDA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Zacks ? 24 days ago LQDA +4.93% CSTL 3 US Growth Stocks With High Insider Ownership And Earnings Growth Up To 61% As the U.S. stock market continues to reach new heights, driven by strong performances in sectors like semiconductors and artificial intelligence, investors are increasingly focused on growth opportunities with robust fundamentals. In this environment, companies with high insider ownership and significant earnings growth potential can be particularly attractive, as they often indicate strong alignment between management and shareholder interests. Simply Wall St. ? last month LQDA +4.93% TOST GCT Liquidia Corp (LQDA) Q2 2024 Earnings Call Highlights: Navigating Challenges and Opportunities ... Despite a drop in revenue, Liquidia Corp (LQDA) remains optimistic with strong cash reserves and promising developments in its YUTREPIA program. GuruFocus.com ? last month LQDA +4.93% Liquidia Technologies (LQDA) Surges 11.2%: Is This an Indication of Further Gains? Liquidia Technologies (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. Zacks ? last month LQDA +4.93% SCPH -3.18% Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute Liquidia Shares Jump After US Supreme Court Rejects United Therapeutics' Appeal in Patent Dispute PREMIUM MT Newswires ? last month LQDA +4.93% UTHR United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalidDecisions that Liquidia does not infringe any valid claims of the three patents originally asserted by United Therapeutics are now final and not subject to further appeal MORRISVILLE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare card GlobeNewswire ? last month LQDA +4.93% Liquidia and Pharmosa Biopharm Expand Collaboration to Develop?Sustained Release Inhaled Treprostinil (L606) Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhereLiquidia also obtains rights to Pharmosa’s next-generation nebulizers for use with L606Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America MORRISVILLE, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients GlobeNewswire ? last month LQDA +4.93% Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting MORRISVILLE, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today the company will present a poster and host a medical theater at the CHEST 2024 annual meeting hosted by the American College of Chest Physicians on October 6-9, 2024, in Boston. Rajeev Saggar, MD, Chief Medical Officer at Liquidia, said: “Every year, CHEST unites the next generation GlobeNewswire ? last month LQDA +4.93% Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock? Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. Zacks ? 2 months ago LQDA +4.93% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return LQDA S&P 500 YTD -11.47% +25.15% 1-Year +61.36% +31.54% 3-Year +150.00% +27.06%
